Amna Khalifa
Dubai Health Authority, Dubai, UAE
Title: Diabetic kidney disease. Measure to slow the progression to ESRF
Biography
Biography: Amna Khalifa
Abstract
The incidence and prevalence of diabetes mellitus are increasing worldwide, including the burden of its complication. (1) considerable proportion of this burden is attributable to the effect on the on the kidneys, accounting for increased incidence of DKD . (2) IN spite of a well controlled blood sugar and blood pressure , there is a proportion of diabetics who progress to end stage renal failure. Hence pathologic molecular mechanisms of DN, which may provide valuable tools for early diagnosis and prevention of disease have been studied to prevent its progression to end stage renal failure. Currently, there are few therapeutic drugs for DN, which mainly consist of antihypertensive and antiproteinuric measures . current research into original therapies to treat DN is focusing on the intrinsic renal pathways that intervene with intracellular signaling of anti-inflammatory, antifibrotic, and metabolic pathways.
More over early identification of the complications such as anemia, which are common to both DKD and diabetes, (3) are, therefore, an important therapeutic strategy to improve outcomes in patients with DKD.
The guidelines concern several issues as renal replacement modality selection, glycaemic control, the choice of glycaemia controlling drugs and cardiovascular risk management aiming to improve the quality of life of the patients, as well as to reduce the costs of the medical care.